Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET. Investors can access the live webcast through Aura's investor relations website, where it will remain available for replay for 90 days after the presentation.
Aura Biosciences (NASDAQ: AURA), azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie mirate per tumori solidi, ha comunicato la sua partecipazione al 27° Annual Global Investment Conference di H.C. Wainwright.
La CEO, Elisabet de los Pinos, PhD, terrà una presentazione il 10 settembre 2025 alle 11:00 ET. Gli investitori potranno seguire la diretta via webcast sul sito investor relations di Aura; la registrazione resterà disponibile per la visione on demand per 90 giorni dopo l'evento.
Aura Biosciences (NASDAQ: AURA), compañía biotecnológica en fase clínica dedicada al desarrollo de terapias de precisión para tumores sólidos, ha anunciado su participación en la 27.ª Conferencia Global Anual de Inversión de H.C. Wainwright.
La directora ejecutiva, Elisabet de los Pinos, PhD, ofrecerá una presentación el 10 de septiembre de 2025 a las 11:00 a.m. ET. Los inversores podrán ver la transmisión en directo a través de la web de relaciones con inversores de Aura; la grabación estará disponible para reproducción durante 90 días tras la presentación.
Aura Biosciences (NASDAQ: AURA), 고형종양을 위한 정밀 치료제 개발에 주력하는 임상 단계의 바이오테크 기업이 H.C. Wainwright 제27회 연례 글로벌 투자 콘퍼런스에 참가한다고 발표했습니다.
CEO Elisabet de los Pinos, PhD가 2025년 9월 10일 오전 11:00(동부시간)에 발표를 진행합니다. 투자자들은 Aura의 투자자관계 웹사이트에서 실시간 웹캐스트를 시청할 수 있으며, 발표 후 90일간 다시보기로 제공됩니다.
Aura Biosciences (NASDAQ: AURA), société biotechnologique en phase clinique dédiée au développement de thérapies ciblées pour tumeurs solides, a annoncé sa participation à la 27e conférence mondiale annuelle sur l'investissement de H.C. Wainwright.
La directrice générale, Elisabet de los Pinos, PhD, prononcera une présentation le 10 septembre 2025 à 11h00 ET. Les investisseurs pourront suivre la retransmission en direct via le site relations investisseurs d'Aura ; l'enregistrement restera disponible en replay pendant 90 jours après la présentation.
Aura Biosciences (NASDAQ: AURA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung präziser Therapien für solide Tumoren spezialisiert hat, hat seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference angekündigt.
Die Geschäftsführerin, Elisabet de los Pinos, PhD, wird am 10. September 2025 um 11:00 Uhr ET eine Präsentation halten. Investoren können das Live-Webcast über die Investor-Relations-Website von Aura verfolgen; die Aufzeichnung steht 90 Tage nach der Präsentation zum Abruf bereit.
- None.
- None.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025, at 11:00 a.m. ET.
The live webcast of the presentation will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
When is Aura Biosciences (AURA) presenting at the H.C. Wainwright Conference?
Who will represent Aura Biosciences at the H.C. Wainwright Conference?
How can investors access Aura Biosciences' H.C. Wainwright Conference presentation?
What type of company is Aura Biosciences (AURA)?
